Diamond Bar, CA October 12, 2005 Biosense Webster, Inc. today announced that the company has received clearance by the U.S. Food and Drug Administration (FDA) for devices that aid electroanatomical mapping. The CARTO
TM RMT Navigation System, NAVISTAR RMT Steerable Tip Diagnostic Catheter, and REFSTAR
TM RMT Catheter with the QWIKPATCH External Reference Patch products were all designed to integrate with the Niobe Magnetic Navigation System designed by Stereotaxis, Inc. The clearance of these Biosense Webster products by the FDA provides electrophysiologists additional tools and maneuvering capabilities when using the Niobe Magnetic Navigation System to allow doctors to steer a catheter remotely.
Electroanatomical mapping allows you to create a 3D map of the heart showing electrical activity. By developing the 3D map using the Biosense Webster technology, doctors are able to pinpoint the exact timing or voltage of the electrical signal which allows for a more timely diagnosis of the patient's irregular heart beat (arrhythmia).
"This advanced technology from Biosense Webster provides improved capabilities for magnetic maneuvering," said Gery F. Tomassoni, MD, Director, Central Baptist Hospital Cardiac Research, Lexington, Kentucky. "Doctors can now perform high-precision procedures, such as mapping potentially life-threatening arrhythmias, while lowering the risks of radiation exposure."
"We are very pleased with the FDA clearance. Our remote magnetic technology coupled with the Niobe Navigation System marks the beginning of a whole new era of electrophysiological innovation," said Roy Tanaka, president of Biosense Webster.
The products cleared by the FDA include:
CARTOTM RMT System combines unparalleled accuracy and precision in electroanatomical mapping with a new level of navigational control. The integration of the highly advanced Niobe Navigation technology will enable elect
'"/>
12-Oct-2005
Page: 1 2 Related medicine news :1.
W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research2.
AstraZeneca announces SYMBICORT is now available in the US3.
Weill Cornell Medical College announces gifts totaling $400M4.
GSK announces launch of largest ever Phase III trial in lung cancer treatment5.
Elsevier announces launch of Brain Stimulation6.
NSW Premier announces $15M for childrens cancer research7.
National Inventors Hall of Fame announces 2007 inductees8.
Emory University announces new Global Health Institute9.
BioMed Central announces Journal of Medical Case Reports10.
Tibotec Therapeutics announces start of largest US study on HIV treatment in women11.
Wiley announces partnership with NASPGHAN and AASLD